According to a commentary, this study offers substantive evidence that cure of hepatitis C delivered by all-oral direct-acting antiviral regimens is associated with clinical benefits. It notes these findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term hepatitis C related morbidity and mortality. It adds they also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection, and also provide credence to the achievability of the goals set out by WHO, not only to eliminate hepatitis C but also to substantially reduce its complications.